Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph 1/2 Study of Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer(VIKTORY-2)

NCT06085755 is registered in ClinicalTrials.gov with Jeeyun Lee as lead sponsor.

NCT NCT06085755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06085755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph 1/2 Study of Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer(VIKTORY-2)
Lead sponsor
Jeeyun Lee
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 30, 2024
Completion date
December 31, 2026
Enrollment
61 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stomach neoplasm